Brinckerhoff Discusses Recent Federal Circuit Decision on Biosimilar with Bloomberg Law
December 15, 2017
Bloomberg Law Patent, Trademark & Copyright Journal – Daily Edition
Partner Courtenay Brinckerhoff was quoted in a Bloomberg Law Patent, Trademark & Copyright Journal – Daily Edition article, “Biosimilars Statute Trumps State Law, Appeals Court Rules,” about a recent U.S. Court of Appeals for the Federal Circuit ruling on the Biologics Price Competition and Innovation Act.
The court, in a December 14, 2017, ruling, held that the statute, which provides a relatively quick path for biosimilar makers to get new drug products to market, supersedes state law claims. The ruling was the second big win for biosimilar applicants this year. Earlier the U.S. Supreme Court allowed a biosimilar applicant to skip a notice period to a biologic owner before marketing its biosimilar product.
“The decision favors biosimilar applicants in that it forecloses a state law remedy for failing to comply with the BPCIA information exchange procedures, and thereby confirms that doing so is completely optional,” Brinckerhoff said. “Since the field of biosimilar litigation is relatively new, the decision does not upset any long-settled practices, although existing cases may include similar state law claims that may not survive this decision.”
The court, in a December 14, 2017, ruling, held that the statute, which provides a relatively quick path for biosimilar makers to get new drug products to market, supersedes state law claims. The ruling was the second big win for biosimilar applicants this year. Earlier the U.S. Supreme Court allowed a biosimilar applicant to skip a notice period to a biologic owner before marketing its biosimilar product.
“The decision favors biosimilar applicants in that it forecloses a state law remedy for failing to comply with the BPCIA information exchange procedures, and thereby confirms that doing so is completely optional,” Brinckerhoff said. “Since the field of biosimilar litigation is relatively new, the decision does not upset any long-settled practices, although existing cases may include similar state law claims that may not survive this decision.”
People
Related News
May 27, 2025
In the News
Foley's Silicon Valley Corporate Additions Featured in Legal Press
Foley & Lardner LLP partners Gurpreet Bal and Shaalu Mehra are highlighted in legal press for their recent arrival to the firm.
May 21, 2025
In the News
Nathaniel Lacktman Shares Insight on Virtual Second Opinion Programs
Foley & Lardner LLP partner Nathaniel Lacktman highlighted considerations for virtual second-opinion programs (VSOs) in the Physician's Weekly article, "Navigating Licensure Risks in Virtual Second-Opinion Programs."
May 16, 2025
In the News
Foley's East Coast Litigation Additions Highlighted in Legal Press
Foley & Lardner LLP partners Kenneth Breen, Phara Guberman, and Joseph Dowdy are featured across legal press for their recent move to the firm.